Travel Vaccines Market Size & Share Report, 2025 - 2034

Travel Vaccines Market - By Vaccine Type, By Disease Type, By Application, By Age Group, By End Use - Global Forecast, 2025 - 2034

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Data mining sources

1.3.1&nbsp;&nbsp;&nbsp; Global

1.3.2&nbsp;&nbsp;&nbsp; Regional/Country

1.4&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.4.1&nbsp;&nbsp;&nbsp; Base year calculation

1.4.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.6&nbsp;&nbsp;&nbsp; Forecast model

1.7&nbsp;&nbsp;&nbsp; Research assumptions and limitations

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 360&deg; synopsis

2.2&nbsp;&nbsp;&nbsp; Key market trends

2.2.1&nbsp;&nbsp;&nbsp; Regional trends

2.2.2&nbsp;&nbsp;&nbsp; Vaccine type trends

2.2.3&nbsp;&nbsp;&nbsp; Disease type trends

2.2.4&nbsp;&nbsp;&nbsp; Application trends

2.2.5&nbsp;&nbsp;&nbsp; Age group trends

2.2.6&nbsp;&nbsp;&nbsp; End use trends

2.3&nbsp;&nbsp;&nbsp; CXO perspectives: Strategic imperatives

2.3.1&nbsp;&nbsp;&nbsp; Key decision points for industry executives

2.3.2&nbsp;&nbsp;&nbsp; Critical success factors for market players

2.4&nbsp;&nbsp;&nbsp; Future outlook and strategic recommendations

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Rising outbound or international travel

3.2.1.2&nbsp;&nbsp;&nbsp; Growing awareness of preventive measures

3.2.1.3&nbsp;&nbsp;&nbsp; Advancements in vaccine formulation and production efficiency

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Logistical &amp; infrastructure challenges

3.2.2.2&nbsp;&nbsp;&nbsp; Stringent regulatory approval process

3.2.3&nbsp;&nbsp;&nbsp; Market opportunities

3.2.3.1&nbsp;&nbsp;&nbsp; Customized &amp; combination vaccines

3.2.3.2&nbsp;&nbsp;&nbsp; Growing travel and tourism

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Pipeline analysis

3.5&nbsp;&nbsp;&nbsp; Technology landscape

3.5.1&nbsp;&nbsp;&nbsp; Current technological trends

3.5.2&nbsp;&nbsp;&nbsp; Emerging technologies

3.6&nbsp;&nbsp;&nbsp; Regulatory landscape

3.7&nbsp;&nbsp;&nbsp; Gap analysis

3.8&nbsp;&nbsp;&nbsp; Future market trends

3.9&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.10&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.3.1&nbsp;&nbsp;&nbsp; North America

4.3.2&nbsp;&nbsp;&nbsp; Europe

4.3.3&nbsp;&nbsp;&nbsp; Asia Pacific

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Key developments

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Vaccine Type, 2021-2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Mono vaccines

5.3&nbsp;&nbsp;&nbsp; Combination vaccines

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Hepatitis A

6.3&nbsp;&nbsp;&nbsp; Meningococcal diseases

6.4&nbsp;&nbsp;&nbsp; Influenza

6.5&nbsp;&nbsp;&nbsp; Diphtheria, pertussis, tetanus (DPT)

6.6&nbsp;&nbsp;&nbsp; Rabies

6.7&nbsp;&nbsp;&nbsp; Yellow fever

6.8&nbsp;&nbsp;&nbsp; Typhoid

6.9&nbsp;&nbsp;&nbsp; Measles, mumps, and rubella (MMR)

6.10&nbsp;&nbsp;&nbsp; Hepatitis B

6.11&nbsp;&nbsp;&nbsp; Other disease types

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Outbound travel

7.3&nbsp;&nbsp;&nbsp; Domestic travel

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Pediatric

8.3&nbsp;&nbsp;&nbsp; Adult

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; Hospitals

9.2.1&nbsp;&nbsp;&nbsp; Public

9.2.2&nbsp;&nbsp;&nbsp; Private

9.3&nbsp;&nbsp;&nbsp; Specialty clinics

9.4&nbsp;&nbsp;&nbsp; Other end use

Chapter 10&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

10.1&nbsp;&nbsp;&nbsp; Key trends

10.2&nbsp;&nbsp;&nbsp; North America

10.2.1&nbsp;&nbsp;&nbsp;U.S.

10.2.2&nbsp;&nbsp;&nbsp;Canada

10.3&nbsp;&nbsp;&nbsp; Europe

10.3.1&nbsp;&nbsp;&nbsp;Germany

10.3.2&nbsp;&nbsp;&nbsp;UK

10.3.3&nbsp;&nbsp;&nbsp;France

10.3.4&nbsp;&nbsp;&nbsp;Spain

10.3.5&nbsp;&nbsp;&nbsp;Italy

10.3.6&nbsp;&nbsp;&nbsp;Netherlands

10.4&nbsp;&nbsp;&nbsp; Asia Pacific

10.4.1&nbsp;&nbsp;&nbsp;Japan

10.4.2&nbsp;&nbsp;&nbsp;China

10.4.3&nbsp;&nbsp;&nbsp;India

10.4.4&nbsp;&nbsp;&nbsp;Australia

10.4.5&nbsp;&nbsp;&nbsp;South Korea

10.5&nbsp;&nbsp;&nbsp; Latin America

10.5.1&nbsp;&nbsp;&nbsp;Brazil

10.5.2&nbsp;&nbsp;&nbsp;Mexico

10.5.3&nbsp;&nbsp;&nbsp;Argentina

10.6&nbsp;&nbsp;&nbsp; Middle East and Africa

10.6.1&nbsp;&nbsp;&nbsp;South Africa

10.6.2&nbsp;&nbsp;&nbsp;Saudi Arabia

10.6.3&nbsp;&nbsp;&nbsp;UAE

Chapter 11&nbsp;&nbsp;&nbsp;Company Profiles 

11.1&nbsp;&nbsp;&nbsp; Bavarian Nordic

11.2&nbsp;&nbsp;&nbsp; Bharat Biotech

11.3&nbsp;&nbsp;&nbsp; CSL

11.4&nbsp;&nbsp;&nbsp; Dynavax Technologies

11.5&nbsp;&nbsp;&nbsp; Emergent BioSolutions

11.6&nbsp;&nbsp;&nbsp; GlaxoSmithKline plc (GSK)

11.7&nbsp;&nbsp;&nbsp; Meiji Group

11.8&nbsp;&nbsp;&nbsp; Merck

11.9&nbsp;&nbsp;&nbsp; Pfizer

11.10&nbsp;&nbsp;&nbsp; Sanofi

11.11&nbsp;&nbsp;&nbsp; Serum Institute of India

11.12&nbsp;&nbsp;&nbsp; Valneva SE

&nbsp;&nbsp;&nbsp;

Travel Vaccines Market

Get a free sample of this report